All In Biotech

Free tool

FAERS Monitor: Intralipid 30%

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019942 or its brand name (Intralipid 30%, Soybean Oil). Reports on generic versions are filed under their own applications.

Reports

727

Serious

626

86% of reports

Hospitalization

249

Death reported

85

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • chills75
  • pyrexia57
  • parenteral nutrition associated liver disease56
  • nausea53
  • dyspnoea46
  • vomiting45
  • chest discomfort42
  • diarrhoea39
  • off label use35
  • weight decreased35
  • drug ineffective32
  • product dose omission issue29
  • decreased appetite28
  • hyperpyrexia27
  • hypotension24

Reports by year received

View as table
YearReports
20044
20051
20126
201327
201449
201567
201678
201765
201852
201950
202044
202153
202251
202360
202458
202532
202629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,432 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
parenteral nutrition associated liver diseaseSignal5649143.132162.31,002,232
hyperpyrexiaSignal27185.7128.14,747
chillsSignal7518.514.91,232
chest discomfortSignal4211.98.9409
pyrexiaSignal574.83.7169
weight decreasedSignal353.62.665
decreased appetiteSignal283.52.448
hypotensionSignal243.52.340
product dose omission issueSignal292.92.034
vomitingSignal452.82.150
dyspnoeaSignal462.41.835
nausea531.91.524
diarrhoea391.71.312
off label use351.20.81
drug ineffective320.70.54

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.